THE CLINICOPATHOLOGICAL FEATURES OF SERUM CA-19-9-POSITIVE COLORECTAL CANCERS

被引:39
|
作者
UEDA, T
SHIMADA, E
URAKAWA, T
机构
[1] Department of Surgery, Kobe Rosai Hospital of the Labour Welfare Corporation, Chuo-ku, Kobe, 651
来源
关键词
COLORECTAL CANCER; CA; 19-9; LIVER METASTASIS; PROGNOSIS;
D O I
10.1007/BF01884571
中图分类号
R61 [外科手术学];
学科分类号
摘要
The preoperative serum levels of carbohydrate antigen 19-9 (CA 19-9) were determined in 206 patients with colorectal cancer, 52 (25.2%) of whom were found to be positive. All of these patients had advanced cancers and significantly higher incidences of tumor invasion through the muscularis propria (91.3%) and lymph node involvement (54.5%). The incidences of liver metastasis and Dukes' stage D in the CA 19-9-positive group were 38.5% and 42.9%, respectively, significantly higher than those in the CA 19-9-negative group of 6.5% and 14.8%, respectively. Moreover, the incidence of liver metastasis in the CA 19-9-positive group patients with Dukes' stage D cancer was 95.2% (20/21); CA 19-9 showing higher specificity (81.7%) and a more positive predictive value (38.5%) for liver metastasis than the carcinoembryonic antigen (CEA). When a cutoff value of 160 U/ml was used, the specificity and positive predictive value reached 97.7% and 81.0%, respectively. An analysis of response operating characteristic (ROC) curves for liver metastasis revealed that CA 19-9 was more useful than CEA. The long-term survival of the CA 19-9-positive group patients was significantly worse than that of the CA 19-9-negative group patients (P < 0.0001), with no 1.25-year survivors in the former group when the cutoff value of 160 U/ml was used. These results suggest that serum CA 19-9 as a useful pre-operative indicator of liver metastasis and prognosis in colorectal cancer.
引用
收藏
页码:518 / 525
页数:8
相关论文
共 50 条
  • [31] Gene expression profiling:Canonical molecular changes and clinicopathological features in sporadic colorectal cancers
    Jin Cheon Kim
    Seon Young Kim
    Seon Ae Roh
    Dong-Hyung Cho
    Dae Dong Kim
    Jeong Hyun Kim
    Yong Sung Kim
    World Journal of Gastroenterology, 2008, 14 (43) : 6662 - 6672
  • [32] Gene expression profiling: Canonical molecular changes and clinicopathological features in sporadic colorectal cancers
    Kim, Jin Cheon
    Kim, Seon Young
    Roh, Seon Ae
    Cho, Dong-Hyung
    Kim, Dae Dong
    Kim, Jeong Hyun
    Kim, Yong Sung
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (43) : 6662 - 6672
  • [33] Perioperative MVT-5873, a fully human monoclonal antibody against a CA 19-9 epitope, for operable CA 19-9 producing pancreatic cancers, cholangiocarcinomas, and metastatic colorectal cancers.
    Gupta, Shreya
    McDonald, James D.
    Ayabe, Reed, I
    Khan, Tahsin M.
    Gamble, Lauren A.
    Rossi, Alexander J.
    Sinha, Surajit
    Hannah, Cathleen
    Mabry-Hrones, Donna
    Monge, M. Cecilia B.
    Blakely, Andrew M.
    Greten, Tim F.
    Davis, Jeremy L.
    Hernandez, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer
    Rao, Hui
    Wu, Heming
    Huang, Qingyan
    Yu, Zhikang
    Zhong, Zhixiong
    CLINICAL LABORATORY, 2021, 67 (04) : 1079 - 1089
  • [35] Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute
    Zhao, Yajie
    Wang, Chengfeng
    JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 24 (04) : 855 - 865
  • [36] Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute
    Yajie Zhao
    Chengfeng Wang
    Journal of Gastrointestinal Surgery, 2020, 24 : 855 - 865
  • [37] CA 19-9 as a marker for gastrointestinal cancers: a review
    Duffy, MJ
    ANNALS OF CLINICAL BIOCHEMISTRY, 1998, 35 : 364 - 370
  • [38] The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery
    Ryosuke Okamura
    Suguru Hasegawa
    Koya Hida
    Nobuaki Hoshino
    Kenji Kawada
    Kenichi Sugihara
    Yoshiharu Sakai
    International Journal of Clinical Oncology, 2017, 22 : 96 - 101
  • [39] Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
    Morita, S
    Nomura, T
    Fukushima, Y
    Morimoto, T
    Hiraoka, N
    Shibata, N
    DISEASES OF THE COLON & RECTUM, 2004, 47 (02) : 227 - 232
  • [40] Assessment of prognostic values of serum CEA and CA 19-9 concentration in patients with colorectal cancer
    Tuteska, J.
    Arapceska, M.
    Stojkovski, V.
    Gligurovska, J.
    CLINICA CHIMICA ACTA, 2019, 493 : S121 - S121